Paul Bunn Jr., MD

Paul A. Bunn, Jr., MD is Director of the University of Colorado Cancer Center in Denver, where he is the James Dudley endowed Chair of Cancer Research and Professor of Medicine at the University of Colorado Health Sciences Center. He received his medical degree from Cornell University Medical Center in New York. Dr. Bunn completed his internship and residency in medicine at University of California, H.C. Moffitt Hospital in San Francisco and his fellowship in medical oncology at the Medicine Branch of the National Cancer Institute.

Dr. Bunn previously served as chairman of the FDA's Oncology Drug Advisory Committee (ODAC) and served a term as the President of the American Society of Clinical Oncology (ASCO) and two terms on ASCO Board of Directors. He also serves on the Board of Directors of the ASCO Foundation.

Dr. Bunn is also the Executive director, former President of the International Association for the Study of Lung Cancer. He is a former President of the American Association of Cancer Institutes and chairs the Scientific Advisory Board of the Cancer League of Colorado.

Dr. Bunn's research is in the development of novel therapies for lung cancer. He has published 300 original papers with recent publications in Journal of the National Cancer Institute, Journal of clinical Oncology and Clinical Cancer Research.




Scott Z. Fields, MD

Dr. Fields is a Professor of Oncology at the Hofstra University School of Medicine North Shore Long Island Jewish Health System. Previously, Dr. Fields served as Arno Therapeutic’s President and Chief Medical officer from 2007 to 2009. Prior to joining Arno, he was Global Vice President for all therapeutic areas at Eisai (2002 - 2007) where he was responsible for forming their global clinical oncology group. Prior to that, he was Head of the Oncology Therapeutic area for Amgen from 2000 to 2002. From 1995 to 2000, he was Head of Oncology Development and Medical Affairs in North America for Smithkline Beecham, where his group was responsible for the development of Topotecan, the first approved camptothecin. Dr. Fields and his teams have been involved in the development of a number of oncology agents, which include Bexxar, Aranesp, Neulasta, Panitumomab and Kepivance. He is a former Assistant Professor of Medicine, co-director of Bone Marrow Transplant, and Head of Intramural Research at SUNY Upstate Medical Center (1991-1995). In addition, Dr. Fields was involved in the development of the RECIST criteria now routinely used to evaluate response of cancer to treatment. In 2003 and 2004, he was a faculty member of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He has been an Assistant Professor of Medicine at Columbia University Medical Center from 2003 - present. Dr. Fields received his M.D. from SUNY Downstate and trained in Internal Medicine, Oncology and Hematology at Columbia University Medical Center.




Henry Friedman, MD

Henry S. Friedman, M.D. is the James B. Powell, Jr. Professor of Neuro-Oncology and Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University. Dr. Friedman received his medical degree from the State University of New York at Syracuse.

Dr. Friedman is an internationally recognized neuro-oncologist with a career-long interest in the treatment of children and adults with brain and spinal cord tumors, and has written hundred of articles on both the clinical and laboratory investigation of these neoplasms. He is the head of the Laboratory of Medical/Pediatric Neuro-Oncology, and is an Associate Chief of the Preuss Laboratory for Brain Tumor Research.




Francis J. Giles, MD

Francis J. Giles, MD is Deputy Director of the Cancer Therapy & Research Center (CTRC) at the UT Health Science Center and Director of The Institute for Drug Development, CTRC's internationally acclaimed oncology drug development program. Dr. Giles holds the AT&T Distinguished Chair in Drug Development at CTRC. Dr. Giles is also the Chief of the Division of Hematology and Medical Oncology at the University of Texas Health Science Center at San Antonio.

Dr. Giles interests are in developmental therapeutics, the leukemias, multiple myeloma, the lymphomas and stem cell transplantation. Dr. Giles has worked extensively in the area of biologic response modifiers in the leukemias, myeloproliferative disorders and multiple myeloma. He was the first to document the efficacy of alpha interferon in essential thrombocythemia and pioneered the use of interferon-based combination regimens in chronic myeloid leukemia. He has also published extensively on cytogenetic abnormalities in the leukemias and has contributed about 300 medical papers and abstracts to the medical literature. Dr. Giles is particularly dedicated to the therapy of patients with advanced and/or refractory disease. As principal investigator on numerous clinical studies, he has been involved in the study of many novel agents including DaunoXome, topotecan, MGBG, liposomal ATRA, Mylotarg, PIXY321, DX-8951f, Troxacitabine, MGI-114, IB-367, Ramoplanin, STI571, SU5416, NX211 and Genasense. Dr. Giles is founder and chairman of the International Oncology Study Group, which conducts oncology studies in the U.S. and in the Middle and Far East. He received his medical training at the National University of Ireland Galway.




Michael Grever, MD

Michael Grever, MD serves as Chairman of the Department of Internal Medicine at The Ohio State University, where he serves as Professor and Charles A. Doan Chair of Medicine, Department of Internal Medicine, Co-Program Leader, Experimental Therapeutics Program, James Comprehensive Cancer Center and Solove Research Institute, Associate Dean for Medical Services, College of Medicine, Professor of Pharmacology, Department of Pharmacology, School of Biomedical Science, College of Medicine and Public Health. From 1980 to 1989, he directed the interdisciplinary oncology unit at the Ohio State University Hospitals. In 1989, he was appointed deputy director of the Division of Cancer Treatment at the National Cancer Institute, and later became director of NCI's Developmental Therapeutics Program, when he left to become the Director, Division of Hematologic Malignancies, and Professor of Oncology at Johns Hopkins Oncology.